| Drug NDC: | 43742-0869 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Detox Iii |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Proprietary Name Base: | Detox |
| The base of the Brand/Proprietary name excluding its suffix. | |
| Proprietary Name Suffix: | III |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Conium Maculatum, Dulcamara, Echinacea (angustifolia), Aesculus Hippocastanum, Antimonium Tartaricum, Ascorbic Acid, Coccus Cacti, Galium Aparine, Gentiana Lutea, Geranium Robertianum, Pulsatilla (vulgaris), Sarcolacticum Acidum, Lymph Node (suis), Sulphur, Glandula Suprarenalis Suis, L-phenylalanine, Calcarea Phosphorica, Ferrum Phosphoricum, Hepar Suis, Hypothalamus (suis), Spleen (suis), Cortisone Aceticum, Mercurius Solubilis, Baryta Carbonica, Glyphosate, Funiculus Umbilicalis Suis |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Deseret Biologicals, Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ANTIMONY POTASSIUM TARTRATE - 6 [hp_X]/mL ASCORBIC ACID - 6 [hp_X]/mL BARIUM CARBONATE - 28 [hp_X]/mL BISPHENOL A - 12 [hp_C]/mL BROMINE - 12 [hp_C]/mL CHLORINE - 12 [hp_C]/mL CONIUM MACULATUM FLOWERING TOP - 4 [hp_X]/mL CORTISONE ACETATE - 13 [hp_X]/mL ECHINACEA ANGUSTIFOLIA - 4 [hp_X]/mL ESCHERICHIA COLI - 30 [hp_C]/mL Load more... FERRUM PHOSPHORICUM - 10 [hp_X]/mL GALIUM APARINE - 6 [hp_X]/mL GENTIANA LUTEA ROOT - 6 [hp_X]/mL GERANIUM ROBERTIANUM - 6 [hp_X]/mL GLYPHOSATE - 1000 [hp_X]/mL HORSE CHESTNUT - 6 [hp_X]/mL HYDROFLUORIC ACID - 12 [hp_C]/mL IODINE - 12 [hp_C]/mL LACTIC ACID, L- - 6 [hp_X]/mL LIOTHYRONINE - 10 [hp_C]/mL MERCURIUS SOLUBILIS - 13 [hp_X]/mL PHENYLALANINE - 8 [hp_X]/mL PORK LIVER - 10 [hp_X]/mL PROTORTONIA CACTI - 6 [hp_X]/mL PULSATILLA VULGARIS - 6 [hp_X]/mL SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS - 9 [hp_C]/mL SOLANUM DULCAMARA TOP - 4 [hp_X]/mL SULFUR - 8 [hp_X]/mL SUS SCROFA ADRENAL GLAND - 8 [hp_X]/mL SUS SCROFA BONE MARROW - 12 [hp_C]/mL SUS SCROFA HYPOTHALAMUS - 10 [hp_X]/mL SUS SCROFA LYMPH - 8 [hp_X]/mL SUS SCROFA SPLEEN - 10 [hp_X]/mL SUS SCROFA TONSIL - 6 [hp_C]/mL SUS SCROFA UMBILICAL CORD - 6 [hp_C]/mL TRIBASIC CALCIUM PHOSPHATE - 10 [hp_X]/mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 06 Oct, 2016 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 28 Aug, 2023 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 23 Dec, 2025 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Deseret Biologicals, Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000193618 M0001797 N0000175946 M0021977 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | DL6OZ476V3 PQ6CK8PD0R 6P669D8HQ8 MLT3645I99 SBV4XY874G 4R7X1O2820 Q28R5GF371 883WKN7W8X VB06AV5US8 514B9K0L10 Load more... 91GQH8I5F7 Z4B6561488 S72O3284MS R5I1HK0UBL 4632WW1X5A 3C18L6RJAZ RGL5YE86CZ 9679TC07X4 F9S9FFU82N 06LU7C9H1V 324Y4038G2 47E5O17Y3R 6EC706HI7F LZB7TFX1LT I76KB35JEV Y3V16D4PV4 KPS1B1162N 70FD1KFU70 398IYQ16YV VP2CN2G7Y8 N6R0856Z79 33A7VYU29L 92AMN5J79Y TB08NIC03W 118OYG6W3H 91D9GV0Z28 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Vitamin C [EPC] l-Triiodothyronine [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class CS: | Ascorbic Acid [CS] Triiodothyronine [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Ascorbic Acid [CS] Blood Coagulation Factor [EPC] Calcium [CS] Cations Divalent [CS] Corticosteroid Hormone Receptor Agonists [MoA] Corticosteroid [EPC] Increased Coagulation Factor Activity [PE] Triiodothyronine [CS] Vitamin C [EPC] l-Triiodothyronine [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 43742-0869-1 | 30 mL in 1 BOTTLE, DROPPER (43742-0869-1) | 06 Oct, 2016 | 28 Aug, 2023 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.